{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T20:30:09Z","timestamp":1771533009299,"version":"3.50.1"},"reference-count":50,"publisher":"Impact Journals, LLC","issue":"11-12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes Cancer"],"published-print":{"date-parts":[[2015,11,24]]},"DOI":"10.18632\/genesandcancer.88","type":"journal-article","created":{"date-parts":[[2016,1,20]],"date-time":"2016-01-20T19:52:08Z","timestamp":1453319528000},"page":"462-471","source":"Crossref","is-referenced-by-count":19,"title":["Multiple myeloma cell lines and primary tumors proteome: protein biosynthesis and Immune system as potential therapeutic targets"],"prefix":"10.18632","volume":"6","author":[{"given":"Rodrigo Carlini","family":"Fernando","sequence":"first","affiliation":[{"name":"Departamento de Oncologia Cl\u00ednica e Experimental, Disciplina de Hematologia e Hemoterapia, Universidade Federal de S\u00e3o Paulo, UNIFESP, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabricio de","family":"Carvalho","sequence":"additional","affiliation":[{"name":"Departamento de Oncologia Cl\u00ednica e Experimental, Disciplina de Hematologia e Hemoterapia, Universidade Federal de S\u00e3o Paulo, UNIFESP, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego Robles","family":"Mazzotti","sequence":"additional","affiliation":[{"name":"Departamento de Psicobiologia, Universidade Federal de S\u00e3o Paulo, UNIFESP, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriane Feij\u00f3","family":"Evangelista","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Pio XII - Hospital de C\u00e2ncer de Barretos, Barretos, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter Mois\u00e9s","family":"Tobias Braga","sequence":"additional","affiliation":[{"name":"Departamento de Oncologia Cl\u00ednica e Experimental, Disciplina de Hematologia e Hemoterapia, Universidade Federal de S\u00e3o Paulo, UNIFESP, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria de Lourdes","family":"Chauffaille","sequence":"additional","affiliation":[{"name":"Departamento de Oncologia Cl\u00ednica e Experimental, Disciplina de Hematologia e Hemoterapia, Universidade Federal de S\u00e3o Paulo, UNIFESP, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana Franco","family":"Paes Leme","sequence":"additional","affiliation":[{"name":"Laborat\u00f3rio de Espectrometria de Massas, Laborat\u00f3rio Nacional de Bioci\u00eancias, LNBio, Conselho Nacional de Pesquisa em Energia e Materiais, CNPEM, Campinas, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisele Wally Braga","family":"Colleoni","sequence":"additional","affiliation":[{"name":"Departamento de Oncologia Cl\u00ednica e Experimental, Disciplina de Hematologia e Hemoterapia, Universidade Federal de S\u00e3o Paulo, UNIFESP, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Solly S. Remarks on the pathology of mollities ossium with cases. Med Chir Trans. 1844; 27: 435-461. [PubMed]","DOI":"10.1177\/095952874402700129"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Kyle RA, Rajkumar SV. Multiple myeloma ASH 50th anniversary review multiple myeloma. Blood [Internet]. 2008; 111(6): 2962\u201372. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=2265446&tool=pmcentrez&rendertype=abstract.","DOI":"10.1182\/blood-2007-10-078022"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009; 23(1): 3-9. [PubMed] https:\/\/doi.org\/10.1038\/leu.2008.291.","DOI":"10.1038\/leu.2008.291"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Terpos E. Multiple myeloma. Ann Oncol. 2010; 21(Suppl 7): vii143-50. [PubMed]","DOI":"10.1093\/annonc\/mdq370"},{"key":"5","unstructured":"American Cancer Society. What are the key statistics about multiple myeloma? [Internet]. Atlanta: American Cancer Society; [updated on 2015 Mar 09; cited on 2015 Jun 27]; Available from: http:\/\/www.cancer.org\/cancer\/multiplemyeloma\/detailedguide\/multiple-myeloma-keystatistics"},{"key":"6","unstructured":"Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, http:\/\/seer.cancer.gov\/csr\/1975_2012\/, based on November 2014 SEER data submission, posted to the SEER web site, April 2015."},{"key":"7","doi-asserted-by":"crossref","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008; 111: 2516\u201320.","DOI":"10.1182\/blood-2007-10-116129"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Laubach JP, Richardson PG, Anderson KC. The evolution and impact of therapy in multiple myeloma. Med Oncol. 2010; 27(Suppl. 1): S1-S6. [PubMed]","DOI":"10.1007\/s12032-010-9442-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Mbeunkui F, Johann DJ. Cancer and the tumor microenvironment: A review of an essential relationship. Cancer Chemother Pharmacol. 2009; 63(4): 571\u201382. [PubMed] https:\/\/doi.org\/10.1007\/s00280-008-0881-9.","DOI":"10.1007\/s00280-008-0881-9"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Corn PG. The tumor microenvironment in prostate cancer: Elucidating molecular pathways for therapy development. Cancer Manag Res. 2012; 4(1): 183\u201393. [PubMed] https:\/\/doi.org\/10.2147\/CMAR.S32839.","DOI":"10.2147\/CMAR.S32839"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Zhou J, Mauerer K, Farina L, Gribben JG. The role of the tumor microenvironment in hematological malignancies and implication for therapy. Front Biosci. 2005; 10: 158196. [PubMed]","DOI":"10.2741\/1642"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006; 42(11): 1564-73. [PubMed]","DOI":"10.1016\/j.ejca.2005.12.025"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Ge F, Tao S, Bi L, Zhang Z, Zhang XE. Proteomics: addressing the challenges of multiple myeloma MM: the disease proteomics technologies. 2011; 43(2): 89-95. [PubMed]","DOI":"10.1093\/abbs\/gmq120"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Cumova J, Potacova A, Zdrahal Z, Hajek R. Proteomic analyses in multiple myeloma research. Mol Biotechnol. 2011; 47(1): 83\u201393. [PubMed]","DOI":"10.1007\/s12033-010-9326-x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Lokhorst HM, Plesner T, Gimsing P, et al. Phase I\/II dose-escalation study of Daratumumab in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2013; 31(Suppl; abstr 8512).","DOI":"10.1200\/jco.2013.31.15_suppl.8512"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Maglott D. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 2004; 33(Database issue):D54-8 [PubMed] https:\/\/doi.org\/10.1093\/nar\/gki031.","DOI":"10.1093\/nar\/gki031"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Katz BZ. Adhesion molecules-The lifelines of multiple myeloma cells. Semin Cancer Biol. 2010; 20(3):186-95. [PubMed]","DOI":"10.1016\/j.semcancer.2010.04.003"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Neri P, Bahlis NJ. Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. Curr Cancer Drug Targets. 2012; 12(7): 776-96. [PubMed]","DOI":"10.2174\/156800912802429337"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Bhat M, Robichaud N, Hulea L, Sonenberg N, Pelletier J, Topisirovic I. Targeting the translation machinery in cancer. Nat Publ Gr. 2015; 14(4): 261-78. [PubMed]","DOI":"10.1038\/nrd4505"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Agnelli L, Fabris S, Bicciato S, Basso D, Baldini L, Morabito F, Verdelli D, Todoerti K, Lambertenghi-Deliliers G, Lombardi L, Neri Al. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol. 2007; 136: 565-73. [PubMed]","DOI":"10.1111\/j.1365-2141.2006.06467.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, Carpten J, Gertz M, Rajkumar SV, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007; 67: 2982\u20139. [PubMed]","DOI":"10.1158\/0008-5472.CAN-06-4046"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Weinhold N, Moreaux J, Raab MS, Hose D, Hielscher T, Benner A, Meissner T, Ehrbrecht E, Brough M, Jauch A, Goldschmidt H, Klein B, Moos Ml. NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm. Genes, Chromosomes & Cancer. 2010; 49: 333-41. [PubMed]","DOI":"10.1002\/gcc.20745"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Maggi LB, Jr., Kuchenruether M, Dadey DY, Schwope RM, Grisendi S, Townsend RR, Pandolfi PP, Weber JD. Nucleophosmin serves as a rate-limiting nuclear export chaperone for the Mammalian ribosome. Mol Cell Biol. 2008; 28: 7050\u201365. [PubMed] https:\/\/doi.org\/10.1128\/MCB.01548-07.","DOI":"10.1128\/MCB.01548-07"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Craig EA. Chaperones: helpers along the pathways to protein folding. Science. 1993; 260(5116): 1902-3. [PubMed]","DOI":"10.1126\/science.8100364"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Hartl FU. Molecular chaperones in cellular protein folding. Nature. 1996; 381(6583): 571-9. [PubMed]","DOI":"10.1038\/381571a0"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Hartl FU,Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science. 2002; 295(5561): 1852-8. [PubMed]","DOI":"10.1126\/science.1068408"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Muralidharan S, Mandrekar P. Cellular stress response and innate immune signaling: integrating pathways in host defense and inflammation. J Leukoc Biol. 2013; 94(6): 1167-84. [PubMed] https:\/\/doi.org\/10.1189\/jlb.0313153.","DOI":"10.1189\/jlb.0313153"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Udono H, Ichiyanagi T, Mizukami S, Imai T. Heat shock proteins in antigen trafficking--implications on antigen presentation to T cells. Int J Hyperthermia. 2009; 25(8): 617-25. [PubMed]","DOI":"10.3109\/02656730902902183"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Zhang L, Fok JHL, Davies FE. Heat shock proteins in multiple myeloma. Oncotarget. 2014; 5(5): 1132-48. [PubMed] https:\/\/doi.org\/10.18632\/oncotarget.1584.","DOI":"10.18632\/oncotarget.1584"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Trepel J. Targeting the dynamic HSP90 complex in cancer.Nat. Rev. Cancer. 2010; 10(8): 537-49. [PubMed]","DOI":"10.1038\/nrc2887"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Chatterjee M, Andrulis M, Stuhmer T, Muller E, Hofmann C, Steinbrunn T, Heimberger T, Schraud H, Kressmann S, Einsele H and Bargou RC. The PI3K\/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica. 2012; 98(7):1132-41. [PubMed] https:\/\/doi.org\/10.3324\/haematol.2012.066175.","DOI":"10.3324\/haematol.2012.066175"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Davenport EL, Zeisig A, Aronson LI, Moore HE, Hockley S, Gonzalez D, Smith EM, Powers MV, Sharp SY, Workman P, Morgan GJ and Davies FE. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. Leukemia. 2010; 24(10):1804-7. [PubMed]","DOI":"10.1038\/leu.2010.168"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Zhang L, Fok JJ, Mirabella F, et al. Hsp70 inhibition induces myeloma cell death via the intracellular accumulation of immunoglobulin and the generation of proteotoxic stress. Cancer Letters. 2013; 339(1): 49-59. [PubMed] https:\/\/doi.org\/10.1016\/j.canlet.2013.07.023.","DOI":"10.1016\/j.canlet.2013.07.023"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape.Nat Immunol. 2002; 3: 991\u20138 [PubMed]","DOI":"10.1038\/ni1102-991"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Swann JB, Smyth MJ. Immune surveilance of tumors. J Clin Invest. 2007; 117(5): 1137-46. [PubMed] https:\/\/doi.org\/10.1172\/JCI31405.","DOI":"10.1172\/JCI31405"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004; 22 :329\u201360. [PubMed]","DOI":"10.1146\/annurev.immunol.22.012703.104803"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100(1): 57-70.","DOI":"10.1016\/S0092-8674(00)81683-9"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Aptsiauri N, Cabrera T, Mendez R, Garcia-Lora A, Ruiz-Cabello F, Garrido F. Role of altered expression of HLA class I molecules in cancer progression. Adv Exp Med Biol. 2007; 601: 123-31. [PubMed]","DOI":"10.1007\/978-0-387-72005-0_13"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Klippel ZK, Chou J, Towlerton AM, Voong LN, Robbins P, Bensinger WI, Warren EHl. Immune escape from NY-ESO1-specific T cell therapy via loss of heterozygosity in the MHC. Gene Ther. 2014; 21(3): 337-42. [PubMed] https:\/\/doi.org\/10.1038\/gt.2013.87.","DOI":"10.1038\/gt.2013.87"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Ricklin, D, Lambris, JD. Complement-targeted therapeutics. Nat Biotechnol. 2007; 25: 1265-75. [PubMed] https:\/\/doi.org\/10.1038\/nbt1342.","DOI":"10.1038\/nbt1342"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Kraut EH, Sagone AL Jr. Alternative pathway of complement in multiple myeloma. Am J Hematol. 1981; 11(4): 335-45. [PubMed]","DOI":"10.1002\/ajh.2830110402"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Lugassy G, Platok I, Schlesinger M. Hypocomplementemia in multiple myeloma. Leuk Lymphoma. 1999; 33(3-4): 36570. [PubMed]","DOI":"10.3109\/10428199909058437"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Macor P, Tedesco F. Complement as effector system in cancer immunotherapy. Immunol Lett. 2007; 111(1): 6-13. [PubMed]","DOI":"10.1016\/j.imlet.2007.04.014"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Carroll MC. CD21\/CD35 in B cell activation. Semin Immunol. 1998; 10(4): 279-86. [PubMed]","DOI":"10.1006\/smim.1998.0120"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Murray ME, Gavile CM, Nair JR, Koorella C, Carlson LM, Buac D, Utley A, Chesi M, Bergsagel PL, Boise LH, Lee KP. CD28-mediated pro-survival signaling induces chemotherapeutic reistance in multiple myeloma. Blood. 2014; 123(24): 3770-9. [PubMed] https:\/\/doi.org\/10.1182\/blood-2013-10-530964.","DOI":"10.1182\/blood-2013-10-530964"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Caraux A, Klein B, Paiva B, Bret C, Schmitz A, Fuhler GM, Bos NA, Johnsen HE, Orfao A, Perez-Andres M. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica. 2010; 95(6):1016-20.","DOI":"10.3324\/haematol.2009.018689"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36(3): 842\u201354.","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Greipp PR, Miguel JS, Dune BGM, Crowley JJ, Barlogie B, Blad\u00e9 J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwing H, Morgan G, et al. International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15): 3412\u201320. [PubMed]","DOI":"10.1200\/JCO.2005.04.242"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Shert T, Kyle RA, Lin Y, Russel J, Kumar S, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clinic Proc. 2013; 88(4): 360-76. [PubMed]","DOI":"10.1016\/j.mayocp.2013.01.019"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analyses of large gene lists using DAVID Bioinformatics Resources. Nature Protoc. 2009; 4(1): 4457. [PubMed]","DOI":"10.1038\/nprot.2008.211"}],"container-title":["Genes &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.genesandcancer.com\/lookup\/doi\/10.18632\/genesandcancer.88","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T14:31:09Z","timestamp":1598797869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.genesandcancer.com\/lookup\/doi\/10.18632\/genesandcancer.88"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,24]]},"references-count":50,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["88","26807199"],"URL":"https:\/\/doi.org\/10.18632\/genesandcancer.88","relation":{},"ISSN":["1947-6027"],"issn-type":[{"value":"1947-6027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,24]]}}}